Epilepsy is a serious, chronic neurological disorder characterized by recurrent spontaneous seizures that affects about 50 million people worldwide. Antiepileptic drugs typically control seizures in two-thirds of patients but probably do not alter the underlying pathophysiology 1 . The development of symptomatic epilepsy is thought to involve altered expression of ion channels, synaptic remodeling, inflammation, gliosis and neuronal death, among other factors [2] [3] [4] [5] . However, few antiepileptogenic interventions targeting these processes have shown sufficient efficacy in vivo 1 , and our understanding of the cell and molecular mechanisms of epileptogenesis is incomplete.
Epilepsy is a serious, chronic neurological disorder characterized by recurrent spontaneous seizures that affects about 50 million people worldwide. Antiepileptic drugs typically control seizures in two-thirds of patients but probably do not alter the underlying pathophysiology 1 . The development of symptomatic epilepsy is thought to involve altered expression of ion channels, synaptic remodeling, inflammation, gliosis and neuronal death, among other factors [2] [3] [4] [5] . However, few antiepileptogenic interventions targeting these processes have shown sufficient efficacy in vivo 1 , and our understanding of the cell and molecular mechanisms of epileptogenesis is incomplete.
Evidence is emerging that miRNAs may be crucial to the pathogenesis of several neurological disorders 6, 7 , including epilepsy 8, 9 . MiRNAs are a family of small (~22 nt), endogenously expressed noncoding RNAs that regulate mRNA translation by imperfect basepairing interactions within the 3′ untranslated region 10, 11 . Depending on the degree of sequence complementarity, miRNA binding, which occurs with the help of Argonaute proteins within the RNA-induced silencing complex (RISC), results in either cleavage of the target mRNA or a reduction in its translational efficiency 10, 11 .
MiR-134 is a brain-specific, activity-regulated miRNA that has been implicated in the control of neuronal microstructure 12, 13 . Pyramidal cells are the most common neurons in the neocortex and hippocampus 2 . They are the major source of intrinsic excitatory cortical synapses, and their dendritic spines are the main postsynaptic target of excitatory synapses, with their spine size acting as an index of synaptic strength [14] [15] [16] . Spine remodeling occurs during learning and memory formation, as well as in the setting of neuropsychiatric disorders and pathological brain activity [17] [18] [19] [20] [21] . Spine collapse is mediated in part by the N-methyl-d-aspartate (NMDA)-receptor-dependent and calcium-dependent depolymerization of actin by cofilin 19, 22, 23 . LIM kinase-1 (Limk1) phosphorylates cofilin and inactivates the ability of cofilin to depolymerize actin, and loss of Limk1 results in abnormal spine morphology 24 . In hippocampal neurons, miR-134 targets Limk1 mRNA, thereby preventing Limk1 protein translation 13 . Overexpression of miR-134 in vitro has been reported to reduce spine volume 13 , whereas overexpression of miR-134 in vivo reduces total dendritic length 25 and abrogates long-term potentiation 26 . Mice haploinsufficient for the miRNA biogenesis component DiGeorge syndrome critical region gene 8 do not produce several mature miRNAs, including miR-134, and have lower hippocampal spine density compared to wild-type mice 27 . Spine loss may have divergent consequences according to context 28 , promoting excitability 29 or uncoupling NMDA-receptor-driven currents in neurons and preventing excitotoxicity 30 .
Here we investigated the role of miR-134 in epilepsy and explored the in vivo effect of inhibiting miR-134. We report that miR-134 is upregulated a r t i c l e s 1 0 8 8 VOLUME 18 | NUMBER 7 | JULY 2012 nature medicine in experimental and human epilepsy and show that silencing miR-134 generates a seizure-refractory state and attenuates epileptic seizures and the pathophysiological features of temporal lobe epilepsy (TLE).
RESULTS

MiR-134 is regulated by status epilepticus and in epilepsy
We first investigated whether pathologic brain activity in vivo affects miR-134 levels. We triggered prolonged seizures (status epilepticus) in C57BL/6 mice by intra-amygdala microinjection of the glutamate receptor agonist kainic acid 31, 32 . The resultant seizures caused neuronal damage mainly within the hippocampal CA3 subfield (Fig. 1a) .
To identify the cell populations expressing miR-134 in vivo, we performed in situ hybridization on tissue sections from C57BL/6 control mice labeled with a probe specific for mature miR-134. We detected a strong signal in the soma of hippocampal pyramidal neurons and hilar interneurons, as well as in neurons in the neocortex and amygdala ( Fig. 1b and Supplementary Fig. 1) .
Real-time quantitative PCR (qPCR) analysis showed that status epilepticus resulted in an increase in mature miR-134 levels in the ipsilateral CA3 (P = 0.016) and CA1 (P = 0.035) subfields (Fig. 1c) . The levels of mature miR-134 were not changed in the undamaged contralateral CA3 subfield (Supplementary Fig. 2a) . Nonharmful, nonconvulsive seizures induced by a low dose of systemic kainic acid, a model of epileptic preconditioning 33 in which status epilepticus does not develop, did not alter miR-134 levels compared to vehicle controls in the CA3 (P = 0.89) or CA1 subfields (P = 0.56) (n = 6 mice per group; data not shown).
To determine whether miR-134 was functional, we measured its levels within the RISC, where targeting of miRNAs to mRNA occurs 34 , in control mice and in mice after status epilepticus. We eluted Argonaute-2 from the CA3 subfield 35, 36 and extracted miRNA. We detected a low level of miR-134 in the RISC in the controls, whereas the levels of Argonaute-2-bound miR-134 were higher (P = 0.035) in mice in which we induced status epilepticus (Fig. 1d) . Protein concentrations of the miR-134 target, Limk1 (ref. 13 ), were lower (P = 0.001) in mice after status epilepticus than in the controls (Fig. 1e) .
We next investigated whether miR-134 levels and the expression of Limk1 were altered in experimental epilepsy. Recurrent spontaneous indicates the sense-labeled control section as a control for probe specificity. (c) Real-time qPCR measurement of miR-134 (normalized to RNU19) for the CA3 and CA1 24 h after status epilepticus (SE). n = 5 mice per group. *P < 0.05 compared to Cont subfield by t test. (d) Argonaute-2 (Ago2)-immunoprecipitated (IP) miR-134 from control mice and mice 24 h after status epilepticus. n = 3 mice per group. *P < 0.05 compared to Cont by t test. (e) Limk1 western blot and densitometry. Actin was used as the loading control. n = 5 mice per group. **P < 0. seizures emerge 3-4 d after status epilepticus in the model we used 31, 33 , and within 3 weeks, the mice show pathologic hallmarks of TLE, including neuron loss and astrogliosis (Fig. 1f) . MiR-134 levels were elevated in the CA3 subfield 3 weeks after status epilepticus (P = 0.049) and 1 (P = 0.003) and 3 (P = 0.008) weeks after status epilepticus in the CA1 subfield compared to controls (Fig. 1g ). Limk1 protein concentrations followed an opposite trend and were lower (P = 0.028) in epileptic mice than control mice (Fig. 1h) . The concentrations of cAMP responsive element binding protein 1 (Creb1), another validated miR-134 target 26 , were also lower in epileptic mice than control mice (Supplementary Fig. 2b ).
We next analyzed surgically obtained temporal lobe material from individuals with pharmacoresistent TLE. We detected higher levels (P = 0.029) of mature miR-134 in the TLE specimens compared to autopsy control samples from people who died of causes unrelated to neurological disease (Fig. 1i) . This difference was not an artifact of postmortem delay (Supplementary Fig. 2c-e) . Protein concentrations of LIMK1 were lower (P = 0.039, t test) in individuals with TLE compared to the autopsy controls (Fig. 1i) .
In vivo depletion of miR-134 using antagomirs To explore the function of miR-134 in vivo, we injected mice with locked nucleic acid (LNA) 3′ cholesterol-conjugated oligonucleotides ('antagomirs') [36] [37] [38] [39] . We injected antagomirs targeting miR-134 (Ant-134) (Supplementary Fig. 3a ) or a nontargeting scrambled sequence (Scr) into the mouse ventricle (intracerebroventricularly, i.c.v.) (Supplementary Fig. 3b ) and measured the miRNA levels 1, 4, 8 and 12 h later and then after 1, 3, 5 and 7 d and after 1 and 2 months. Knockdown of miR-134 was first evident 12 h after injection of 0.12 nmol Ant-134 ( Supplementary Fig. 4a-d) , and by 24 h after injection, the levels of miR-134 in the hippocampus of these mice were reduced by over 95% (P = 0.005) (Fig. 2a) . This is similar to effects reported for antagomirs in other tissues 37 . Hippocampal levels of an unrelated miRNA, miR-19a, were not changed by injection of Ant-134 (Fig. 2b) . Increasing the amount of Ant-134 injected to 1 nmol seemed to produce off-target knockdown of miRNAs ( Supplementary Fig. 4e,f) . The miR-134 levels began to recover by 7 d after Ant-134 injection, although they remained lower than the miR-134 levels in the mice injected with Scr at 1 month after injection (P = 0.034), which is consistent with other reports 37 , and were no longer different from the levels in mice injected with Scr (P = 0.469) by 2 months after injection (Fig. 2c) .
Brains from mice injected with the antagomirs had grossly normal anatomy (data not shown). We found no evidence of hippocampal neuronal death when we stained sections from the mice injected with antagomirs for Fluoro-Jade B (FJB), DNA fragmentation (terminal deoxynucleotidyl dUTP nick end labeling; TUNEL) 40 and the neuronal marker NeuN (Fig. 2d,e and data not shown) .
To determine whether the reduction in the levels of miR-134 had any gross effects on mouse behavior, we performed ethological tests 41 . We injected mice with either Scr or Ant-134 and assessed them 24 h later. We found no differences in measures of animal exploratory activity including ambulatory counts, distance traveled or vertical counts between the two groups ( Fig. 2f) , suggesting that silencing of miR-134 does not alter normal exploratory activities.
MiR-134 antagomirs reduce pyramidal neuron spine density
Because in vitro and in vivo evidence supports a role for miR-134 in controlling dendritic spine morphology 13, 25, 27 , we examined whether antagomirs caused changes to dendritic spines in vivo. We microinjected Lucifer yellow into individual CA3 pyramidal neurons in hippocampal slices from control mice 24 h after injection of 0.12 nmol Ant-134 or Scr and imaged them using confocal microscopy, as previously described 42, 43 (Fig. 3a,b) .
We analyzed 218 neurons in the Scr-injected mice (n = 7) and 181 neurons in the Ant-134-injected mice (n = 7). The structures of the basal dendritic trees were grossly normal in both groups, as were the distributions of spines ( Fig. 3c-e) . Dendrites from the Scr-injected mice had an average of 68 nodes (ramifications) compared to 72 nodes in the Ant-134-injected mice. The number of ramification points per µm was also similar in the two groups (0.0127 nodes per µm in the Scr-injected mice compared to 0.0131 nodes per µm in the Ant-134-injected mice). We then analyzed spine density, assessing a total length of 5,343.7 µm of dendrites in the Scr-injected mice (7,455 spines) and a similar length (5,477.5 µm) of dendrites in the Ant-134-injected mice (6,196 spines) . Spine density in the Scr-injected mice was within the expected range 42 (Fig. 3d-f) . Notably, spine density was 21% lower (P = 0.037) in Ant-134-injected mice than in the Scr-injected mice ( Fig. 3d-f) . Thus, injecting miR-134 antagomirs in vivo results in a reduction in spine density. 
Silencing miR-134 reduces status epilepticus and neuronal death
To test the idea that antagomirs might influence pathologic brain activity in vivo, we compared seizures evoked by intra-amygdala microinjection of kainic acid in mice 24 h after injection with either Scr or Ant-134 ( Fig. 4 and Supplementary Fig. 3c ). There was no difference in basal electroencephalography (EEG) measures between the two groups of mice ( Supplementary Fig. 5a ). Scr-injected mice experienced typical status epilepticus, comprising episodes of high-amplitude, high-frequency discharges (HAHFDs) 44 ( Fig. 4a-c; compare Fig. 4c to Fig. 1a ). An EEG analysis revealed that the duration of the HAHFDs (P = 0.0051), which are associated with damage-causing pathologic activity 45 , and total EEG power (P = 0.033) were lower in Ant-134-injected mice compared to Scr-injected mice ( Fig. 4a-c ). This effect was qualitatively similar to the seizure suppression observed in mice given lorazepam 10 min before injection of kainic acid (compare Fig. 4c to Supplementary Fig. 5b ). MiR-134 levels were lower (P = 0.0078) in mice injected with Ant-134 before intra-amygdala injection of kainic acid compared to the mice injected with Scr ( Fig. 4d and Supplementary Fig. 6a ). Limk1 protein concentrations (Fig. 4e) and the concentrations of Creb1 (Supplementary Fig. 6b ) were lower after status epilepticus in Scrinjected mice than in Ant-134-injected mice (P = 0.018), which had similar levels as nonseizure controls.
We next examined hippocampal damage in tissue sections from Scr-injected and Ant-134-injected mice. Scr-injected mice had typical CA3 lesions 24 h after status epilepticus, with extensive staining of neurons for FJB and TUNEL and a loss of NeuN staining ( Fig. 5a-f (Fig. 5a-f) .
To specifically link the neuroprotective effects of antagomirs to miR-134 and Limk1, we treated cultures of primary hippocampal neurons from C57BL/6 mice with kainic acid to model excitotoxic injury. Treatment of hippocampal neurons with kainic acid increased miR-134 levels (P = 0.019) (Fig. 5g) . Next, neurons were co-transfected with shRNAs that targeted Limk1 (Fig. 5h) , and either Scr or Ant-134, and then treated 48 h later with kainic acid. Ant-134 prevented kainicacid-induced neurotoxicty in hippocampal neurons co-transfected with a non-targeting shRNA, and this protective effect was blocked in neurons cotransfected with shRNA targeting Limk1 (Fig. 5i,j) .
Silencing miR-134 reduces spontaneous recurrent seizures Based on our findings so far, we hypothesized that silencing miR-134 might also affect epilepsy. To avoid a confounding influence of shortened status epilepticus duration or neuroprotection on epileptogenesis 40, 46 , we injected antagomirs 1 h after triggering status epilepticus with intraamygdala kainic acid. An analysis of EEG measures confirmed that when we injected antagomirs 1 h after kainic acid injection, there was no difference in duration of HAHFDs during status epilepticus between the Ant-134-injected and Scr-injected groups (Fig. 6a) . In addition, CA3 damage assessed 24 h after triggering status epilepticus was similar between the Ant-134-injected and Scr-injected mice (Fig. 6b,c) .
We then equipped groups of mice with EEG telemetry units 31 and undertook continuous EEG recording for 2 weeks after status epilepticus. In agreement with the normal course of epilepsy in this model 31 , mice injected with Scr after status epilepticus experienced the first spontaneous seizures on the third day, and all mice were epileptic by the fourth day after status epilepticus (Fig. 6d,e and Supplementary  Fig. 6c ). The median epileptic seizure count during 14 d of monitoring of Scr-injected mice was 25 (range 8-79), with 200 epileptic seizures recorded in total for all the Scr-injected mice over this time period (Fig. 6d and Supplementary Fig. 6c ). In contrast, only 60% of mice injected with Ant-134 had had a spontaneous seizure by the eleventh day after status epilepticus ( Fig. 6d and Supplementary  Fig. 6c) ; one mouse had only a single seizure on day 14 and another had no seizures in the 14 d after status epilepticus (Fig. 6d) . Ant-134-injected mice had a median epileptic seizure count of 2 during the 14-d recording period (range 0-7), with just 16 epileptic seizures recorded in total for these mice during the 2 week recording period (P = 0.0001, compared to the Scr-injected group by two-way ANOVA) (Fig. 6e) . The total amount of time spent in seizures also differed between the two groups, with Scr-injected mice spending more time in seizures then Ant-134-injected mice (P < 0.001 by two-way ANOVA; Supplementary Fig. 6c ). The durations of the individual epileptic seizures were similar between the groups (Supplementary Fig. 6d ). Silencing miR-134 alters pathologic hallmarks of TLE Progressive neuron loss, gliosis and rearrangement of mossy fibers are common pathological hallmarks of TLE 47, 48 . We therefore examined whether Ant-134 altered the underlying pathology in the telemetry-equipped mice. Hippocampal CA3 neuron counts in the Ant-134-injected mice were higher than in the Scr-injected mice at the end of epilepsy monitoring, and astrogliosis was lower in the Ant-134-injected mice than in the Scr-injected mice (Fig. 6f) . Neuropeptide Y (NPY) staining, an index of increasing reorganization of the hippocampus 33, 49 , in Scr-injected mice (Fig. 6g) was similar to the previously reported scores in epileptic mice 33 , whereas the NPY scores in the Ant-134-injected mice were lower (P = 0.008) than in the Scr-injected mice (Fig. 6g) .
To investigate whether the reduced epileptic seizure rates were the result of an antiepileptogenic effect or a prolonged anticonvulsant effect of Ant-134, we performed additional experiments.
We first measured miR-134 levels in Ant-134-injected mice at the end of 14 d of telemetry recordings, which established that the miR-134 levels were ~55% of those in the Scr-injected mice ( Supplementary  Fig. 7a ). Reducing miR-134 levels to ~55% of Scr in additional mice by injecting Ant-134 did not produce an anticonvulsant effect against kainic-acid-induced status epilepticus ( Supplementary  Fig. 7b,c) . Likewise, mice subjected to kainic-acid-induced status epilepticus 14 d after i.c.v. injection with Ant-134, when levels of miR-134 are ~70% of those in Scr-injected mice ( Supplementary  Fig. 7d ), were as sensitive to kainic-acid-induced status epilepticus as Scr-injected mice (Supplementary Fig. 7e-h) , and mice were not protected against status epilepticus-induced hippocampal damage (Supplementary Fig. 7i,j) .
Finally, longer-term video monitoring revealed that mice injected with Ant-134 after status epilepticus had fewer generalized tonicclonic seizures and more seizure-free days at up to 2 months after injection compared to Scr-injected mice, although the seizure rates did increase toward the rate of Scr-injected mice in three out of the 5 Ant-134-injected mice (Fig. 6h,i and Supplementary Fig. 8 ).
DISCUSSION
Our study shows that silencing miR-134 in mice using antagomirs suppresses evoked seizures, the occurrence of spontaneous seizures and the associated pathologic hallmarks of epilepsy. These are the first in vivo data, to our knowledge, to show that inhibition of a single mature miRNA can alter pathologic electrical activity in the brain, and they offer a new therapeutic target for the treatment of epilepsy. An association between seizures and changes in miRNA expression has been suggested by recent profiling work 8, 9, 36, 50 and by the phenotype of mice lacking Dicer 51 , although our experiments are the first, to our knowledge, to link upregulation of miR-134 to evoked, harmful seizures and chronic epilepsy. Brief, nonharmful generalized seizures were insufficient to alter miR-134 expression. This suggests that in vivo regulation of miR-134 is not only a response to increased neuronal activity 13 but is also coupled to epileptic or pathogenic brain activity. Crucially, our miRNA silencing experiments support a role for miR-134 in facilitating pathologic neuronal activity in vivo because status epilepticus was potently suppressed in mice in which miR-134 was depleted by antagomirs. Notably, the seizure-suppressing effect of the antagomirs was nearly comparable to that of benzodiazepines 45, 46, 52 . Injecting antagomirs before status epilepticus also protected against seizure-induced hippocampal damage. This probably arises because of the resulting shortened seizure duration 46, 52 , but antagomirs also inhibited direct kainic acid toxicity in vitro. Our in vitro experiments also implicated Limk1 in the mechanism of protection, but rescuing Creb1 may also contribute 53 , and our data are consistent with the neuroprotective effect of sirtuin 1, which negatively regulates miR-134 expression in brain 26 .
Despite progress in understanding the pathogenesis of epilepsy, few studies targeting epileptogenic processes have shown sufficient efficacy at reducing the occurrence, course or severity of the disease 1,54 . A second major finding here was that silencing miR-134 after status epilepticus resulted in a substantial reduction in the number of epileptic seizures in mice. Epilepsy developed normally in Scr-injected mice 31 , whereas spontaneous seizures seldom occurred in the Ant-134-injected mice. Thus, the effect of Ant-134 injection after status epilepticus was superior to that of neuroprotection by other means applied at the time of status epilepticus 40, 55 and was comparable to or exceeded the performance of other experimental antiepileptogenic treatments 1 . Did the antagomirs interrupt epileptogenesis or simply prevent epileptic seizures from occurring as a result of a prolonged anticonvulsant effect, or did they work in a manner similar to antiepileptic drugs? We detected spontaneous seizures, albeit infrequently, in the mice treated with antagomirs, and the increase in seizure rates over extended monitoring in these mice supports the interpretation of a prolonged anticonvulsant or antiepileptic effect. Nevertheless, seizure rates in these mice never recovered to baseline, and seizure frequency 2 months after status epilepticus, a time when antagomir suppression of miR-134 was no longer occurring, was over 70% lower than baseline, so an antiepileptogenic effect is possible. Additional experiments examining seizure frequency at time points later than 2 months after antagomir administration will be required to distinguish between these possibilities.
The mechanism by which miR-134 antagomirs suppress seizures is unknown, but our study offers the possibility that the effect is through changes to dendritic spines. The finding that Ant-134 reduced hippocampal CA3 dendritic spine density in vivo was notable and contrasts with reports that spine size, not density, is controlled by miR-134 (ref. 13) . Thus, a different phenotype results from miR-134 inhibition in vivo, which may be explained by the scale of miRNA suppression achieved, the distribution of the antagomir (somal compared to dendritic), the targets affected or the potency of LNA-modified antagomirs over 2′-O-methyl oligonucleotides 39 . Coincidently, a similar reduction in spine density was reported in mice lacking an miRNA biogenesis component in which the hippocampal levels of mature miR-134 were also reduced 27 . A key target of miR-134 is Limk1, which regulates dendritic spine dynamics 13 . Limk1 protein concentrations followed an opposite pattern as miR-134 expression, and miR-134 silencing prevented seizure-induced downregulation of Limk1, although other explanations for a decrease in spines are possible 15, 56 . Could the reduction in spines account for the suppression of seizures? Dendritic spines are targets of excitatory axons in the brain 14, 15 . Although spines have been suggested to operate as barriers against potentially harmful afferent input 28 , our data are consistent with evidence showing that spine loss reduces excitatory responses 17, 57 and transient spine reduction uncouples excitotoxic NMDA-mediated signaling 30 . The antagomirs seem to curtail pathologic activity in the brain without impairing tonic neuronal communication; an impairment would have been detected by the ethogram, and this result is consistent with reports that a ~20% reduction in the number of hippocampal pyramidal neuron spines does not alter basal neurotransmission 58 . Spine-localized synaptic signaling is also implicated in the pathogenesis of TLE 3 , but whether a similar mechanism may account for the seizure-suppressive effects of miR-134 silencing is unknown. Loss of Limk1, which was countered with antagomirs, can result in increased hippocampal excitability 24 . However, other miR-134 targets with effects on excitability and seizure suppression are known, so we cannot exclude the involvement of these other targets in the effects we observed 26, 53 .
Although the therapeutic application of miR-134 antagomirs for status epilepticus is probably barred by a need for pretreatment, the longevity of the suppression after a single injection, consistent with antagomir data from mouse and primate experiments 37, 39 , suggests applications in refractory epilepsy or in disease modification in the wake of epilepsy-precipitating injuries. Alternate routes for antagomir delivery, such as an intranasal route, which has been considered for antiepileptic drug delivery 59 , may avoid the blood-brain barrier exclusion of antagomirs in vivo 37 and may facilitate translation to the clinic for the treatment of epilepsy.
METhODS
Methods and any associated references are available in the online version of the paper. (20-22 g ) male C57BL/6 mice were purchased from Harlan. Food and water was available to the mice ad libitum. Induction of status epilepticus was performed as described previously 31 . Mice were anesthetized with isoflurane and placed in a mouse-adapted stereotaxic frame. After making a midline scalp incision, the bregma was located, and three partial craniectomies were performed for the placement of skull-mounted recording screws (Bilaney Consultants). A fourth craniectomy was drilled for the placement of a guide cannula (coordinates from the bregma: anterior-posterior (AP) = -0.94 mm, lateral (L) = -2.85 mm) based on a stereotaxic atlas 60 . The cannula and electrode assembly was fixed in place, and the mouse was placed in an open Perspex box, which allowed free movement. The EEG was recorded using a Grass Comet digital EEG. After the baseline EEG was established, the mouse was lightly restrained while an injection cannula was lowered to 3.75 mm below the brain surface for injection of kainic acid (Sigma-Aldrich) or vehicle (PBS pH adjusted to 7.4) into the basolateral amygdala nucleus. After 40 min, all mice received lorazepam (Ativan, 6 mg per kg body weight,intraperitoneally (i.p.)). Mice were recorded for up to 1 h thereafter before being disconnected and placed in a warmed recovery chamber. Nonharmful seizures were induced by a single injection (i.p.) of kainic acid (15 mg per kg body weight), as previously described 36 .
EEG analysis during status epilepticus. EEG was analyzed using TWin software, and the duration of the HAHFDs, also termed type 4 seizures 45 , was calculated between the time of kainic acid injection and the time of lorazepam administration by an observer blinded to the treatment group. Additional frequency and amplitude analyses of EEG data were performed by uploading the data to an automated program for EEG analysis (LabChart Pro v7 software, ADInstruments Ltd). Analysis of spontaneous seizures using EEG telemetry. Epilepsy monitoring by implanted EEG telemetry units was performed as previously described 31, 55 . EEG data were acquired with EEG transmitters (Model:F20-EET, Data Systems International) configured to record a two-channel EEG that was skull-affixed over the dorsal hippocampus and the temporal cortex when the mice were under anesthesia at the time of surgery for intra-amygdala injection. Transmitter units were placed in a subcutaneous pocket along the dorsal flank. Continuous EEG data were collected for 14 consecutive days after status epilepticus. EEG data were reviewed and manually scored by an observer unaware of the experimental treatment, with epileptic seizures being defined as high-frequency (>5 Hz), highamplitude (>2× baseline) polyspike discharges of ≥5 s duration.
Analysis of spontaneous seizures by continuous video monitoring.
Mice were subjected to intra-amygdala kainic-acid-induced status epilepticus and then injected 1 h later with Scr or Ant-134 i.c.v., as described above. Mice were allowed to recover and were then housed in pairs (the mice were distinguished by ear clips) in clear Perspex cages (dimensions: 32 cm (long) × 17 cm (wide) × 14 cm (deep)). Webcam-style cameras connected to laptop computers were placed 40 cm from the cages in a room equipped with safe lights for nighttime recordings. Images were captured using VirtualDub 1.9.11 (SourceForge.net) with a sampling rate of 10 frames per second and a data transfer rate of 140 kb s -1 . Videos from 5 d of continuous monitoring during weeks 3-4 and weeks 7-8 after status epilepticus were reviewed by an observer unaware of the experimental treatment. Seizures were counted using a modified six-point Racine scale for mice. The scores were determined as follows: 2, forelimb and or tail extension, rigid posture; 3, repetitive movements, head bobbing; 4, rearing and falling; 5, continuous rearing and falling; or 6, severe tonic-clonic seizures. Clinical events scoring below 2 such as sudden freezing and immobility were not included. The numbers of seizures per day were analyzed using Poisson regression with robust standard errors to express the experimental effect as an incidence rate ratio. The average Racine score and the number of seizure-free days were compared using the Wilcoxon Mann-Whitney test.
Mouse tissue samples. Mice were killed by pentobarbital overdose and perfused with ice-cold saline to remove the intravascular blood components. The brains to be used for molecular and biochemical work were microdissected over wet ice, with the hippocampus being further subdivided to obtain the separate CA3-enriched portion, as previously described 55 . For histology, mice were either perfusion fixed with paraformaldehyde (4%) or their brains were fresh frozen in 2-methylbutane (at −30 °C).
Human samples. This study was reviewed and approved by the Beaumont Hospital Ethics (Medical Research) Committee (approval REC 05/18), and informed consent was obtained from each subject. Subjects (n = 3) were determined to have medically intractable TLE and had been referred by an epileptologist (N.D.) for surgical resection of the temporal lobe (D.F.O.) after neurological assessment, video EEG recordings and neuroimaging (magnetic resonance imaging). All patients were taking antiepileptic drugs before surgery. Each temporal lobe neocortex sample was inspected by a pathologist (M.A.F.) and deemed to be absent of any obvious neuron loss or lesion. Subject 1 was a 27-year-old male who underwent right posterior temporal lobectomy. Subject 2 was a 53-year-old male who underwent right anterior temporal lobectomy. Subject 3 was a 45-yearold male who underwent temporal lobectomy. Temporal neocortex samples were flash frozen in liquid nitrogen and stored at -70 °C until use. Each sample was divided and used for either miRNA measurement or protein analysis.
Human control samples were also fresh frozen, were donated by people who died of causes not related to known neurological disease and were obtained from the Brain and Tissue Bank for Developmental Disorders at the University of Maryland, Baltimore, Maryland, USA. Samples were all from people of European ancestry (mean age 26.3 years, range 25-28 years). The causes of death for these individuals were (for subjects C1 and C2) multiple injuries from a road traffic accident and (for subject C3) cardiac tamponade. The average autopsy delay after death was 6.7 h (range 7-12 h).
Simulated postmortem delay.
To simulate the postmortem delay in the human subjects, mice were killed, and the cortices from the temporal association region were extracted either immediately (0 h) or were removed after a delay of 6 h or 12 h (to simulate the postmortem interval). Samples were then processed for miRNA measurement.
Histopathology. Coronal sections from two levels of the dorsal (septal) hippocampus were analyzed (rostral, AP = −1.46 mm; medial, AP = −1.70 mm). For detection of neurodegeneration, sections were stained using FJB 55 (Millipore). Irreversible DNA damage was detected using a fluorescein-based TUNEL kit (Promega). For immunohistochemistry, sections were postfixed, permeabilized, blocked in 5% goat serum and then incubated overnight with antibodies to NeuN (1:400, Clone A60, Millipore), GFAP (1:400, G9269) or NPY (1:1,000, N9528) (both from SigmaAldrich). Sections were washed and incubated with secondary antibodies raised in goat conjugated with Alexa Fluor 488 (for NeuN) or Alexa Fluor 568 (for GFAP and NPY) (BioSciences Ltd). Sections were mounted with medium containing DAPI (Vector Laboratories Ltd). Sections were examined using a Hamamatsu Orca 285 camera attached to a Nikon 2000s epifluorescence microscope (Micron Optical). Counts were the average of those from two adjacent sections of the ipsilateral CA3 subfield scored by an observer blinded to the experimental treatment.
Synaptic reorganization was assessed by an observer blinded to the experimental treatment in NPY-stained sections. Immunostaining was rated from
